Introduction: The accelerated approval of resmetirom by the U.S. Food and Drug Administration (FDA) in March 2024 marks a major milestone in the treatment of metabolic dysfunction-associated steatohepatitis (MASH), formerly known as nonalcoholic steatohepatitis (NASH), particularly in patients with moderate to advanced liver fibrosis (stages F2–F3)
566 Reached2 Comments
Study evaluating Effectiveness of Bacillus clausii for Treatment of Rotavirus Infection
1303 Reached4 Comments6 Likes
SECCA for Managing Anal Incontinence
203 Reached2 Comments2 Likes
Single-incision Laparoscopy for Gastrostomy
407 Reached2 Comments1 Likes
Abnormal Biliary Imaging in Patient with history of Hypothyroidism
116 Reached1 Comments2 Likes
Psychological Manifestations Of IBS
662 Reached1 Comments1 Likes